Edition:
United Kingdom

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

183.10USD
8:13pm GMT
Change (% chg)

$-0.45 (-0.25%)
Prev Close
$183.55
Open
$182.89
Day's High
$184.30
Day's Low
$182.14
Volume
585,824
Avg. Vol
1,184,245
52-wk High
$201.23
52-wk Low
$152.16

Chart for

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN... (more)

Overall

Beta: 1.40
Market Cap(Mil.): $135,588.20
Shares Outstanding(Mil.): 729.67
Dividend: 1.15
Yield (%): 2.48

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

CORRECTED-Novartis readies to auction U.S. generic pills business -sources

Feb 16 Switzerland's Novartis AG is preparing to auction its U.S. generic pill business, looking to shed a unit that has struggled amid fierce price competition, people familiar with the matter said on Friday.

16 Feb 2018

BRIEF-Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of Blincyto

* AMGEN ANNOUNCES FDA ADVISORY COMMITTEE MEETING TO REVIEW POTENTIAL NEW USE OF BLINCYTO® (BLINATUMOMAB)

14 Feb 2018

Amgen profit misses Street view; sees broad tax reform benefits

Amgen Inc on Thursday reported a fourth-quarter profit well below Wall Street estimates, hurt by a steep decline in sales of blockbuster rheumatoid arthritis drug Enbrel and higher-than-expected expenses, and its shares fell nearly 2 percent.

01 Feb 2018

UPDATE 3-Amgen profit misses Street view; sees broad tax reform benefits

Feb 1 Amgen Inc on Thursday reported a fourth-quarter profit well below Wall Street estimates, hurt by a steep decline in sales of blockbuster rheumatoid arthritis drug Enbrel and higher-than-expected expenses, and its shares fell nearly 2 percent.

01 Feb 2018

Amgen quarterly profit misses, 2018 EPS outlook ahead of Street view

Feb 1 Amgen Inc on Thursday reported fourth-quarter profit well below Wall Street estimates, as a steep decline in sales of blockbuster rheumatoid arthritis drug Enbrel and higher-than-expected expenses hit results.

01 Feb 2018

BRIEF-Amgen Inc Q4 Loss Per Share $5.89

* AMGEN QTRLY LOSS PER SHARE $5.89; QTRLY ADJUSTED EARNINGS PER SHARE $2.89; QTRLY REVENUE $5.80 BILLION, DOWN 3 PERCENT

01 Feb 2018

BRIEF-Amgen Receives CHMP Positive Opinion To Add Updated Overall Survival Data To Kyprolis Label

* AMGEN RECEIVES CHMP POSITIVE OPINION TO ADD UPDATED OVERALL SURVIVAL DATA TO KYPROLIS® (CARFILZOMIB) LABEL Source text for Eikon: Further company coverage:

30 Jan 2018

Novartis poised for growth as CEO hands baton to U.S. newcomer

BASEL Novartis expects to return to operating profit growth this year, with new Chief Executive Vas Narasimhan inheriting the Swiss drugmaker as revenue from its latest medicines accelerates and the impact of expiring patents fades.

24 Jan 2018

Novartis poised for growth as CEO hands baton to U.S. newcomer

BASEL Novartis expects to return to operating profit growth this year, with new Chief Executive Vas Narasimhan inheriting the Swiss drugmaker as revenue from its latest medicines accelerates and the impact of expiring patents fades.

24 Jan 2018

BRIEF-Amgen Reports Aimovig Met All Primary, Secondary Endpoints

* AMGEN REPORTS AIMOVIG™ (ERENUMAB) MET ALL PRIMARY AND SECONDARY ENDPOINTS IN UNIQUE PHASE 3B STUDY IN EPISODIC MIGRAINE PATIENTS WHO HAVE FAILED MULTIPLE PRIOR PREVENTIVE TREATMENTS

22 Jan 2018

Earnings vs. Estimates